ONDA, Solution for injection 4 mg / 2 ml ONDA, (Solution for injection 8 mg / 4 ml)

ONDA contains a medicine called ondansetron. This belongs to a group of medicines called anti-emetics.
ONDA is used for:
preventing nausea and vomiting caused by chemotherapy (in adults and children) or radiotherapy for cancer (adults only)
 preventing nausea and vomiting after surgery.
Ask your doctor, nurse or pharmacist if you would like any further explanation about these uses.

a.Do not have ONDA if:
 you are taking apomorphine (used to treat Parkinson's disease)
 you are allergic (hypersensitive) to ondansetron or any of the other ingredients in ONDA (listed in Section 6).
If you are not sure, talk to your doctor, nurse or pharmacist before having ONDA.
b.Take special care with ONDA
Warnings and precautions
Check with your doctor, nurse or pharmacist before having ONDA if:
 you have ever had heart problems (eg congestive heart failure which causes shortness of breath and swollen ankles)
 you have an uneven heart beat (arrhythmias)
- 2 -
 you are allergic to medicines similar to ondansetron, such as granisetron or palonosetron

You have liver problems
you have a blockage in your gut
you have problems with the levels of salts in your blood, such as potassium, sodium and magnesium.
If you are not sure if any of the above apply to you, talk to your doctor, nurse or pharmacist before having ONDA.
c.Taking other medicines and ONDA
Compatibility with intravenous fluids
ONDA injection should only be admixed with those infusion solutions which are recommended:
 Sodium Chloride Intravenous Infusion BP 0.9% w / v
 Glucose Intravenous Infusion BP 5% w / v
 Mannitol Intravenous Infusion BP 10% w / v
Ringers Intravenous Infusion
 Potassium Chloride 0.3% w / v and Sodium Chloride 0.9% w / v Intravenous Infusion BP
 Potassium Chloride 0.3% w / v and Glucose 5% w / v Intravenous Infusion BP
In keeping with good pharmaceutical practice dilutions of ONDA in intravenous fluids should be prepared at the time of infusion or stored at 2-8 ° C for no more than 24 hours before the start of administration.
Compatibility studies have been undertaken in polyvinyl chloride infusion bags and polyvinyl chloride administration sets. It is considered that adequate stability would also be conferred by the use of polyethylene infusion bags or Type 1 glass bottles. Dilutions of ONDA in sodium chloride 0.9% w / v or in glucose 5% w / v have been demonstrated to be stable in polypropylene syringes. It is considered that ONDA diluted with other compatible infusion fluids would be stable in polypropylene syringes.
Compatibility with other drugs
ONDA may be administered by intravenous infusion at 1 mg / hour, eg from an infusion bag or syringe pump. The following drugs may be administered via the Y-site of the ONDA giving set for ondansetron concentrations of 16 to 160 micrograms / ml (eg 8 mg / 500 ml and
8 mg / 50 ml respectively);
Cisplatin: Concentrations up to 0.48 mg / ml (eg 240 mg in 500 ml) administered over one to eight hours.
5- Fluorouracil: Concentrations up to 0.8 mg / ml (eg 2.4 g in 3 liters or 400 mg in 500 ml) administered at a rate of at least 20 ml per hour (500 ml per 24 hours). Higher concentrations of 5-fluorouracil may cause precipitation of ondansetron. The 5-fluorouracil infusion may contain up to 0.045% w / v magnesium chloride in addition to other excipients shown to be compatible.
Carboplatin: Concentrations in the range 0.18 mg / ml to 9.9 mg / ml (eg 90 mg in 500 ml to 990 mg in 100 ml), administered over ten minutes to one hour.
Etoposide: Concentrations in the range 0.14 mg / ml to 0.25 mg / ml (eg 72 mg in 500 ml to 250 mg in 1 liter), administered over thirty minutes to one hour.
Ceftazidime: Doses in the range 250 mg to 2000 mg reconstituted with Water for Injections BP as recommended by the manufacturer (eg 2.5 ml for 250 mg and 10 ml for 2 g ceftazidime) and given as an intravenous bolus injection over approximately five minutes.
- 4 -
Cyclophosphamide: Doses in the range 100 mg to 1 g, reconstituted with Water for Injections BP, 5 ml per 100 mg cyclophosphamide, as recommended by the manufacturer and given as an intravenous bolus injection over approximately five minutes.
Doxorubicin: Doses in the range 10-100 mg reconstituted with Water for Injections BP, 5 ml per 10 mg doxorubicin, as recommended by the manufacturer and given as an intravenous bolus injection over approximately 5 minutes.
Dexamethasone: Dexamethasone sodium phosphate 20 mg may beered as a slow intravenous injection over 2-5 minutes via the Y-site of an infusion set delivering 8 or 16 mg of ondansetronuted in 50-100 ml of dil a compatible infusion fluid over approximately 15 minutes . Compatibility between dexamethasone sodium phosphate and ondansetron has been demonstrated supporting administration of these drugs through the same giving set resulting in concentrations in line of 32 microgram - 2.5 mg / ml for dexamethasone sodium phosphate and 8 microgram - 1 mg / ml for ondansetron.
Please tell your doctor, nurse or pharmacist if you are taking, or have recently taken, or might take any other medicines. This includes medicines that you buy without a prescription and herbal medicines. This is because ONDA can affect the way some medicines work. Also some other medicines can affect the way ONDA works.
In particular, tell your doctor, nurse or pharmacist if you are taking any of the following medicines:
 carbamazepine or phenytoin used to treat epilepsy
 rifampicin used to treat infections such as tuberculosis (TB)
 antibiotics such as erythromycin or ketoconazole
 anti- arrhythmic medicines used to treat an uneven heart beat
 beta-blocker medicines used to treat certain heart or eye problems, anxiety or prevent migraines
 tramadol, a pain killer
medicines that affect the heart (such as haloperidol or methadone)
cancer medicines (especially anthracyclines and trastuzumab).
The SSRIs (Selective of Serotonin the Reuptake Inhibitors) of Used To Treat Depression and / Or of Anxiety Including Fluoxetine, of paroxetine, of sertraline, Fluvoxamine, Citalopram, Escitalopram
• The SNRIs (of serotonin of noradrenaline the reuptake inhibitors) of To Treat Depression And / Or of anxiety Including Venlafaxine, Duloxetine
If the You are not sure if any of the above applies to you, talk to your doctor, nurse or pharmacist before having ONDA.
ONDA should not be given in the same syringe or infusion (drip) as any other medication.
d.Pregnancy and breast-feeding
It is not known if ONDA is safe during pregnancy. If you are pregnant, think you are pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before having ONDA.
Do not breast-feed if you have ONDA. This is because small amounts pass into the mother's milk. Ask your doctor or midwife for advice.
e.Important information about some of the ingredients of ONDA
This medicine contains sodium citrate and sodium chloride. This means that ONDA contains 7 mg of sodium per 4 mg dose, which is less than 1 mmol sodium (23 mg) per dose ie essentially “sodium-free”.

ONDA is normally given by a nurse or doctor. The dose you have been prescribed will depend on the treatment you are having.
Posology and Method of Administration
Chemotherapy and Radiotherapy induced nausea and vomiting
Adults
The emetogenic potential of cancer treatment varies according to the doses and combinations of chemotherapy and radiotherapy regimens used. The route of administration and dose of ONDA should be flexible in the range of 8-32 mg a day and selected as shown below.
Emetogenic chemotherapy and radiotherapy: ONDA can be given either by rectal, oral (tablets or syrup), intravenous or intramuscular administration. For most patients receiving emetogenic chemotherapy or radiotherapy, ONDA 8 mg should be administered as a slow intravenous injection (in not less than 30 seconds) or intramuscular injection immediately before treatment, followed by 8 mg orally twelve hourly. To protect against delayed or prolonged emesis after the first 24 hours, oral or rectal treatment with ONDA should be continued for up to 5 days after a course of treatment.
Highly emetogenic chemotherapy: For patients receiving highly emetogenic chemotherapy, eg high-dose cisplatin, ONDA can be given either by rectal, intravenous or intramuscular administration. ONDA has been shown to be equally effective in the following dose schedules over the first 24 hours of chemotherapy:
 A single dose of 8 mg by slow intravenous injection (in not less than 30 seconds) or intramuscular injection immediately before chemotherapy.
 A dose of 8 mg by slow intravenous injection (in not less than 30 seconds) or intramuscular injection immediately before chemotherapy, followed by two further

intravenous injections (in not less than 30 seconds) or intramuscular doses of 8 mg four hours apart, or by a constant infusion of 1 mg / hour for up to 24 hours.
 A maximum initial dose of 16 mg diluted in 50-100 ml of saline or other compatible infusion fluid (See Instructions for Use / Handling) and infused over not less than 15 minutes immediately before chemotherapy. The initial dose of ONDA may be followed
by two additional 8 mg intravenous doses (in not less than 30 seconds) or intramuscular doses four hours apart.
 A single dose greater than 16 mg must not be given due to dose dependent increase of QT-prolongation risk (see sections 4.4, 4.8 and 5.1 of the SPC).
The selection of dose regimen should be determined by the severity of the emetogenic challenge. The efficacy of ONDA in highly emetogenic chemotherapy may be enhanced by the addition of a single intravenous dose of dexamethasone sodium phosphate, 20 mg administered prior to chemotherapy.
To protect against delayed or prolonged emesis after the first 24 hours, oral or rectal treatment with ONDA should be continued for up to 5 days after a course of treatment.
Pediatric Population:
CINV in children aged ≥ 6 months and adolescents
The dose for CINV can be calculated based on body surface area (BSA) or weight - see below.
ONDA should be diluted in 5% dextrose or 0.9% sodium chloride or other compatible infusion fluid (see Instructions for Use / Handling) and infused intravenously over not less than 15 minutes.
There are no data from controlled clinical trials on the use of ONDA in the prevention of delayed or prolonged CINV. There are no data from controlled clinical trials on the use of ONDA for radiotherapy-induced nausea and vomiting in children.
Dosing by BSA:
ONDA should be administered immediately before chemotherapy as a single intravenous dose of 5 mg / m2. The single intravenous dose must not exceed 8 mg. Oral dosing can commence 12 hours later and may be continued for up to 5 days (see SPC for dosing tables). The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg.
Dosing by bodyweight:
Weight-based dosing results in higher total daily doses compared to BSA-based dosing. ONDA should be administered immediately before chemotherapy as a single intravenous dose of 0.15 mg / kg. The single intravenous dose must not exceed 8 mg. Two further intravenous doses may be given in 4-hourly intervals. Oral dosing can commence 12 hours later and may be continued for up to 5 days. The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg. (see SPC for further details).
Elderly
In patients 65 to 74 years of age, the dose schedule for adults can be followed. All intravenous doses should be diluted in 50-100 ml of saline or other compatible infusion fluid (see Instructions for Use / Handling) and infuse over 15 minutes

In patients 75 years of age or older, the initial intravenous dose of ONDA should not exceed 8 mg. All intravenous doses should be diluted in 50-100 ml of saline or other compatible infusion fluid (see Instructions for Use / Handling) and infused over 15 minutes. The initial dose of 8 mg may be followed by two further intravenous doses of 8 mg, infused over 15 minutes and given no less than four hours apart (see SPC).
Post-Operative Nausea and Vomiting (PONV) Adults
For the prevention of PONV ONDA can be administered orally or by intravenous or intramuscular injection. ONDA may be administered as a single dose of 4 mg given by intramuscular or slow intravenous injection at induction of anaesthesia. For treatment of established PONV a single dose of 4 mg given by intramuscular or slow intravenous injection is recommended.
Children (aged over 1 month and adolescents)
Injection:
For prevention of PONV in paediatric patients having surgery performed under general anaesthesia, a single dose of ONDA may be administered by slow intravenous injection (not less than 30 seconds) at a dose of 0.1 mg / kg up to a maximum of 4 mg either prior to, at or after induction of anaesthesia. For the treatment of PONV after surgery in pediatric
Patients, having surgery performed under general anaesthesia, a single dose of ondansetron may be administered by slow intravenous injection (not less than 30 seconds) at a dose of
0.1 mg / kg up to a maximum of 4 mg. There are no data on the use of ONDA in the treatment of PONV in children below 2 years of age.
Elderly
There is limited experience in the use of ONDA in the prevention and treatment of PONV in the elderly, however ONDA is well tolerated in patients over 65 years receiving chemotherapy.
For all indications: Renal impairment
No alteration of daily dosage or frequency of dosing, or route of administration are required.
Hepatic impairment
Clearance of ONDA is significantly reduced and serum half-life significantly prolonged in subjects with moderate or severe impairment of hepatic function. In such patients a total daily dose of 8 mg should not be exceeded.
Poor sparteine ​​/ debrisoquine metabolism
The elimination half-life of ondansetron is not altered in subjects classified as poor metabolisers of sparteine ​​and debrisoquine. Consequently in such patients repeat dosing will give drug exposure levels no different from those of the general population. No alteration of daily dosage or frequency of dosing are required.
To prevent nausea and vomiting from chemotherapy or radiotherapy in adults

On the day of chemotherapy or radiotherapy
 the usual adult dose is 8 mg given by a slow injection into your vein or muscle, just before your treatment, and another 8 mg twelve hours later. After chemotherapy, your medicine will usually be given by mouth as an 8 mg ONDA tablet or 10 ml (8 mg) ONDA.
On the following days
 the usual adult dose is one 8 mg tablet or 10 ml (8 mg) syrup taken twice a day
 this may be given for up to 5 days.
If your chemotherapy or radiotherapy is likely to cause severe nausea and vomiting, you may be given more than the usual dose of ONDA. Your doctor will decide this.
To prevent nausea and vomiting from chemotherapy in children aged over 6 months and adolescents
The doctor will decide the dose depending on the child's size (body surface area) or weight. Look at the label for more information
On the day of chemotherapy
 the first dose is given by an injection into the vein, just before your child's treatment. After chemotherapy, your child's medicine will usually be given by mouth twelve hours later, as ONDA syrup or a ONDA.
On the following days
 2.5 ml (2 mg) syrup twice a day for small children and those weighing 10 kg or less
 one 4 mg tablet or 5 ml (4 mg) syrup twice a day for larger children and those weighing more than 10 kg
 two 4 mg tablets or 10 ml (8 mg) syrup twice a day for teenagers (or those with a large body surface area)
 these doses can be given for up to five days
To prevent and treat nausea and vomiting after an operation
Adult:
 The usual dose for adults is 4 mg given by a slow injection into your vein or an injection into your muscle. For prevention, this will be given just before your operation.
Children:
 For children aged over 1 month and adolescents the doctor will decide the dose. The maximum dose is 4 mg given as a slow injection into the vein. For prevention, this will be given just before the operation.
Patients with moderate or severe liver problems
The total daily dose should not be more than 8 mg.
If you keep feeling or being sick
ONDA should start to work soon after having the injection. If you continue to be sick or feel sick, tell your doctor or nurse.
If you have more ONDA than you should your
doctor or nurse will give you or your child ONDA so it is unlikely that you or your child will receive too much. If you think you or your child have been given too much or have missed a dose, tell your doctor or nurse.

Like all medicines, ONDA can cause side effects, although not everybody gets them.
Allergic reactions
If you have an allergic reaction, tell your doctor or a member of the medical staff straight away. The signs may include:
 sudden wheezing and chest pain or chest tightness
 swelling of your eyelids, face, lips, mouth or tongue
 skin rash - red spots or lumps under your skin (hives) anywhere on your body
 collapse.
Other side effects include:
Very common (may affect more than 1 in 10 people)
headache.
Common (may affect up to 1 in 10 people)
a feeling of warmth or flushing
 constipation
Changes to liver function test results (if you have ONDA with a medicine called cisplatin, otherwise this side effect is uncommon)
 irritation and redness at the site of injection.
Uncommon (may affect up to 1 in 100 people)
hiccups
low blood pressure, which can make you feel faint or dizzy
uneven heart beat
chest pain
fits
Unusual body movements or shaking.
Rare (may affect up to 1 in 1,000 people)
 feeling dizzy or light headed
 blurred vision
 disturbance in heart rhythm (sometimes causing a sudden loss of consciousness)
Very rare (may affect up to 1 in 10,000 people)
 poor vision or temporary loss of eyesight, which usually comes back within 20 minutes.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.

Protect from light
Store below 30 ° C.
Keep out of the reach and sight of children.
Do not use ONDA after the expiry date which is stated on the carton.